PrescriptionDrugs.org

What to Expect When Starting Tolterodine

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication. Using this site does not create a doctor-patient relationship.

Drug information changes as the FDA updates labeling, and we cannot guarantee it is complete or current. Verify critical details with your pharmacist or physician.

Emergencies: If you think you may have a medical emergency, call 911 immediately. For a suspected overdose, call Poison Control at 1-800-222-1222. Report side effects to the FDA MedWatch program at fda.gov/medwatch or 1-800-FDA-1088.

See our Terms of Use and Editorial Policy.

Introduction

Tolterodine (brand name Detrol, Detrol LA) is a competitive muscarinic receptor antagonist prescribed for the treatment of overactive bladder (OAB) with symptoms of urinary frequency, urgency, and urge incontinence [1]. It works by blocking acetylcholine at muscarinic receptors in the detrusor muscle of the bladder, reducing involuntary contractions that cause urgency and frequency [2]. Tolterodine has some selectivity for bladder muscarinic receptors over salivary gland receptors, resulting in less dry mouth than older anticholinergics like oxybutynin.

Week-by-week timeline

Week 1-2Dry mouth is the most common reason patients discontinue anticholinergic bladder medications. Sugar-free gum or candy can help. The ER formulation causes significantly less dry mouth.

Starting Treatment

Begin with tolterodine 2 mg twice daily (immediate-release) or 4 mg once daily (extended-release/Detrol LA) [1]. Some patients notice reduced urgency within the first few days, but full benefit takes 4-8 weeks. The most common side effects are dry mouth (35% IR, 23% ER), headache (7%), constipation (6%), and dry eyes (3%) [1][2]. The extended-release formulation generally causes fewer anticholinergic side effects due to smoother drug delivery.

Week 2-4If no improvement is seen after 4 weeks, discuss with your doctor — the dose may need adjustment or a different medication class may be more effective.

Early Symptom Improvement

By 2-4 weeks, you should notice a reduction in urgency episodes, urinary frequency, and urge incontinence episodes. Clinical trials showed tolterodine ER reduced urge incontinence episodes by approximately 50% compared to baseline [1]. Nocturia may improve more slowly. If dry mouth or constipation is bothersome, discuss switching from IR to ER formulation or adjusting the dose to 1 mg twice daily (IR) or 2 mg daily (ER) [2].

Week 4-8Combination of medication with behavioral therapy produces better outcomes than either alone for most OAB patients.

Full Therapeutic Effect

By 4-8 weeks, tolterodine reaches its maximum symptomatic benefit [2]. You should notice a meaningful reduction in trips to the bathroom, fewer urgent episodes, and reduced or eliminated incontinence. Your doctor may assess response with a bladder diary (recording fluid intake, voiding frequency, and urgency episodes). Anticholinergic side effects that are going to persist will be apparent by this stage. Consider combining medication with behavioral strategies (bladder training, pelvic floor exercises) for optimal results [2].

Month 3+Consider periodic reassessment of the need for continued treatment, especially in older adults, given the anticholinergic cognitive risk.

Long-Term Management

Tolterodine is generally used long-term for OAB management. Effectiveness is maintained without significant tolerance [1]. However, recent research has raised concerns about long-term anticholinergic burden and cognitive effects, particularly in elderly patients [3]. Discuss the risk-benefit profile periodically with your doctor, especially if you take other medications with anticholinergic properties. Some patients find they can reduce or discontinue the medication after successful bladder retraining.

When to call your doctor

Contact your healthcare provider if you experience:

  • Inability to urinate despite feeling a full bladder (urinary retention) — this is more common in men and requires immediate medical attention [1]
  • Significant confusion, memory problems, or cognitive changes — especially in elderly patients, which may indicate anticholinergic central nervous system effects [2]
  • Severe constipation, abdominal distension, or signs of bowel obstruction [1]
  • Eye pain, visual changes, or seeing halos — may indicate narrow-angle glaucoma exacerbation [1]
  • Severe allergic reaction: rash, hives, swelling of face/lips/tongue, difficulty breathing [1]
  • High fever with decreased sweating — anticholinergics can impair thermoregulation, increasing heat-related illness risk [2]

Tips for getting started

Take the extended-release (Detrol LA) formulation if possible, as it causes less dry mouth and is taken once daily [1]. Swallow ER capsules whole — do not crush or chew. Practice bladder training alongside medication: try to extend the time between voiding by 15-30 minutes every 1-2 weeks. Stay hydrated but avoid excessive fluid intake, caffeinated beverages, alcohol, and spicy foods, which can irritate the bladder. Avoid taking other medications with anticholinergic effects (certain antihistamines, antidepressants) without medical guidance, as the effects are additive [2]. Use caution in hot weather, as anticholinergics reduce sweating.

Frequently asked questions

More about Tolterodine

References

  1. [Regulatory] Detrol (tolterodine) FDA Prescribing Information. Pfizer. Revised 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020771s018lbl.pdf Accessed 2025-01-15.
  2. [Regulatory] Tolterodine. StatPearls [Internet]. National Library of Medicine. Updated 2024. https://www.ncbi.nlm.nih.gov/books/NBK532297/ Accessed 2025-01-15.
  3. [Clinical] Coupland CAC, Hill T, Dening T, et al. Anticholinergic drug exposure and the risk of dementia: a nested case-control study. JAMA Intern Med. 2019;179(8):1084-1093. https://pubmed.ncbi.nlm.nih.gov/31233095/ Accessed 2025-01-15.

Written and fact-checked by PrescriptionDrugs.org Editorial Team

Last updated: